Search our team at AdventHealth Research Institute
-
NCT06307795
A Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThis is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in...
-
NCT05176483
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer ResearchResearch Location: Celebration, FloridaYou are being asked to take part in a clinical research study called STELLAR-002 because you have been diagnosed with cancer or your cancer has worsened since your last treatment. If you join this...
-
NCT05891171
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
This study is currently enrolling.Research Area: Cancer ResearchObjectives: Primary: Dose Escalation: To identify the recommended doses for expansion (RDEs) of NKT3447 in adult subjects with advanced/metastatic solid tumors Dose Expansion: To evaluate the...
-
NCT06172478
A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is not currently enrolling.Research Area: Cancer ResearchThe purpose of this study is to learn more about an investigational drug called patritumab deruxtecan (also known as HER3-DXd or U3-1402), also referred to as “study drug” or “study treatment”...
-
NCT05639751
PRT3789-01: A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThe purpose of this research study is to test the safety of PRT3789 at different dose levels to find out what effects, good and/or bad, PRT3789 has on you and your type of cancer. The information...
-
NCT05914116
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Celebration, FloridaThe main goal of this study is to test whether the study drug is safe and tolerable in patients with advanced/unresectable, or metastatic solid tumors (including small cell lung cancer, non-small cell...
-
NCT05498428
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaThe investigational anti-cancer drugs being studied are called amivantamab (JNJ-61186372) and lazertinib (JNJ-73841937). They are being developed for the treatment of locally advanced or metastatic (i...
-
NCT05858164
An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase alpha inhibitor (DGKai) BAY 2862789 in participants with advanced solid tumors
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThis study is being done to learn more about a new drug called BAY 2862789, an inhibitor of diacylglycerol kinase alpha (DGKα). BAY 2862789 is an immunotherapy drug that has been developed to activate...
-
NCT05592626
CP-START-001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThe purpose of this research study is
To test the safety of study drug STAR0602. To see how well different doses of the study drug STAR0602 are tolerated in different groups of patients. To understand...